StockVS

NASDAQ · Biotechnology · USD

Connect Biopharma Holdings Limited (CNTB) Stock Analysis

Connect Biopharma Holdings Limited (CNTB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CNTB

$0.80

−$0.08 (−8.81%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNTB with… →

CNTB Key Statistics

As of Oct 21, 2026
Trading
Open
$0.88
Previous Close
$0.88
Day's Range
0.79–0.88
52-Week Range
0.85–3.82
Volume
1.57M
Valuation
Market Cap
$55.12M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.19
Financials (FY)
Revenue (FY)
$64.00K−99.75%
Net Income (FY)
−$55.48M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.97M
1-Year Return
−52.78%
Dividend and dates
Avg Volume
3.88M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CNTB closed at $0.80, −52.78% over 1 year.

Connect Biopharma Holdings Limited (CNTB) has a market capitalization of $55.12M.

In fiscal 2025, CNTB reported revenue of $64.00K.

CNTB Stock Return by Calendar Year

Connect Biopharma Holdings Limited (CNTB) return since Mar 2021: what $10,000 became

1 year
$10,000 $4,722
−52.78%
5 years
$10,000 $452
−95.48%
Since Mar 2021
$10,000 $432
−95.68%

If you had invested $10,000 in Connect Biopharma Holdings Limited (CNTB) at the close on March 19, 2021, the earliest close on record here, it would have been worth $432 at the close on October 21, 2026: −95.68% in total, −43.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.70%
2025+104.35%
2024+16.95%
2023+35.94%
2022−83.15%
2021 (partial year)−72.15%

As of October 21, 2026.

CNTB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$64.00K−$55.48M−86,687.5%
2024$26.03M−$15.63M−60.0%
2023$0.00−$62.11M—
2022$0.00−$118.09M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$64.00K—−$58.07M−$55.48M−86,687.5%
2024$26.03M—−$22.45M−$15.63M−60.0%
2023$0.00—−$69.06M−$62.11M—
2022$0.00—−$116.51M−$118.09M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNTB Valuation vs Biotechnology Median

Median of 608 stocks
MetricCNTBBiotechnology medianvs median
P/S ratio18.6613.3040% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Connect Biopharma Holdings Limited (CNTB) at $55.12M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 64 employees.

The most recent close on file for CNTB is $0.80, dated October 21, 2026. That is −$0.08 (−8.81%) against the previous close. Over the past 52 weeks the price has ranged from $0.85 to $3.82.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $64.00K. That is −99.75% against the prior fiscal year, when revenue was $26.03M. The same year closed with a net loss of $55.48M. Trailing earnings per share are −1.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $64.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 18.66 times revenue. On price-to-sales that is 40.35% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Daily returns over the trailing 5 years annualize to a volatility of 115.09%. Over the trailing twelve months the total return is −52.78%. Across 5 years the annualized return works out at −46.18%.

Growth & Income

No dividend is on file for CNTB.

2026 is still running; the total return is −71.70% year to date. Across the complete calendar years on file, 2025 returned +104.35% and 2022 returned −83.15%. Of the 4 complete calendar years on file, 3 finished higher.

Peer Comparison

Connect Biopharma Holdings Limited (CNTB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Connect Biopharma Holdings Limited CNTB $55.12M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Connect Biopharma Holdings Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Visit website →